Department of Neurology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, P. R. China; Institute of Epilepsy, Shandong University, P. R. China.
Institute of Epilepsy, Shandong University, P. R. China.
Epilepsy Behav. 2024 Mar;152:109641. doi: 10.1016/j.yebeh.2024.109641. Epub 2024 Jan 28.
To evaluate the therapeutic efficacy and safety of agomelatine for treating the sleep and mood disorders in epilepsy patients.
Retrospective data were derived from 113 epilepsy patients for at least 8 weeks. All the subjects were divided into two groups, one was treated with agomelatine, the other was treated with escitalopram. Their depression and anxiety states were assessed by Hamilton Depression (HAMD) and Hamilton Anxiety (HAMA) Scales. Sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI).
The HAMA, HAMD and PSQI scores in both groups significantly declined after the treatments with agomelatine and escitalopram. However, the agomelatine group exhibited greater improvement in terms of HAMA and PSQI scores compared to the escitalopram group. No severe adverse events were observed in agomelatine group.
Agomelatine performed better in HAMA and PSQI scores compared to escitalopram, where no significant increase in seizure frequency or side effects were observed. Possibly, agomelatine presents a promising therapeutic option for treating the sleep or mood disorders in epilepsy patients.
评估阿戈美拉汀治疗癫痫患者睡眠和情绪障碍的疗效和安全性。
回顾性数据来自 113 名至少接受 8 周治疗的癫痫患者。所有患者分为两组，一组接受阿戈美拉汀治疗，另一组接受依西酞普兰治疗。采用汉密尔顿抑郁量表（HAMD）和汉密尔顿焦虑量表（HAMA）评估抑郁和焦虑状态，采用匹兹堡睡眠质量指数（PSQI）评估睡眠质量。
阿戈美拉汀和依西酞普兰治疗后，两组的 HAMA、HAMD 和 PSQI 评分均显著下降。然而，与依西酞普兰组相比，阿戈美拉汀组在 HAMA 和 PSQI 评分方面的改善更为显著。阿戈美拉汀组未观察到严重不良事件。
与依西酞普兰相比，阿戈美拉汀在 HAMA 和 PSQI 评分方面表现更好，且未观察到癫痫发作频率或副作用的显著增加。阿戈美拉汀可能为治疗癫痫患者的睡眠或情绪障碍提供了一种有前途的治疗选择。
